Target intelligence / Profile preview

Alpha-synuclein aggregate (α-syn) (α-syn)

Target
α-syn
Molecular classification
Protein aggregate, Amyloid fibril, Intrinsically disordered protein
01

Overview

Alpha-synuclein is a 140-amino acid protein encoded by the SNCA gene, primarily localized in the presynaptic terminals of the central nervous system where it modulates synaptic vesicle trafficking and neurotransmitter release (UniProt P37840). In synucleinopathies such as Parkinson's disease, Dementia with Lewy bodies, and Multiple System Atrophy, the protein misfolds into toxic oligomers and insoluble beta-sheet-rich fibrils that accumulate as Lewy bodies. These aggregated forms are thought to drive neurodegeneration by disrupting cellular membranes, impairing mitochondrial function, and spreading between neurons in a prion-like fashion. Therapeutic strategies targeting these aggregates aim to halt disease progression by inhibiting the aggregation process, neutralizing spreading fibrils with antibodies, or enhancing cellular clearance mechanisms. While several monoclonal antibodies and small molecules are in clinical development, challenges remain regarding blood-brain barrier penetration and the potential impact on the protein's normal physiological roles.

Other names
SNCAAlpha-synuclein fibrilAlpha-synuclein oligomerLewy body proteinNon-amyloid component of plaques (NACP)PARK1PARK4
02

Mechanism of action

The mechanism of action for drugs targeting alpha-synuclein aggregates involves several approaches: passive immunotherapy using monoclonal antibodies to bind extracellular aggregates and prevent their uptake by neighboring neurons (seeding), small molecules that stabilize the monomeric form or disrupt the formation of toxic oligomers and fibrils, and agents that promote the degradation of existing aggregates through the lysosomal or autophagic pathways.

03

Biological functions

Synaptic vesicle traffickingNeurotransmitter release regulationLipid binding
04

Disease associations

Parkinson's diseaseDementia with Lewy bodiesMultiple system atrophyNeurodegenerative disease
05

Safety considerations

Potential disruption of physiological alpha-synuclein function in synaptic vesicle cycling (UniProt P37840)Neuroinflammatory responses to immunotherapyChallenges in blood-brain barrier penetration for large molecules
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Alpha-synuclein seed amplification assay (αSyn-SAA)Cerebrospinal fluid alpha-synuclein levelsSkin biopsy phosphorylated alpha-synucleinDaTscan

Source types: Peer-reviewed publication · Trial registry. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Alpha-synuclein aggregate (α-syn) (α-syn).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-synuclein aggregate (α-syn) (α-syn).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call